NCT04055792View on ClinicalTrials.gov

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Extensive Disease Small Cell Lung Cancer
Interventions
DRUG

Sintilimab

Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks

Trial Locations (1)

450000

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT04055792 - Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC | Biotech Hunter | Biotech Hunter